front 1 Shaping | back 1 Not asking many questions during the first few sessions and introducing graphs and data slowly over time during the psychotropic drug review is an example of using this strategy to develop a relationship with a prescriber. |
front 2 Placebo effect | back 2 Effect is demonstrated when behavior changes in the direction of the drug effect during the condition when there is no active ingredient. |
front 3 Nocebo effect | back 3 has to do with side effects. |
front 4 Alternating Treatment Design | back 4 Can only be used with fast acting drugs with a short half-life. |
front 5 Informed consent | back 5 The participant is informed about the drug effects, side effects and that they have the right to withdraw from the drug evaluation at any time. |
front 6 Capacity to give consent | back 6 Ensures the client understands the risks associated with the medication and can communicate a decision. |
front 7 parametric analysis of drug dosages. | back 7 Ascending, descending, and irregular order are all options when completing a |
front 8 ASCENDING ORDER | back 8 is most commonly used to reduce the risk of side effects, possible toxicity, and ensuring the individual is prescribed the lowest possible dose for a therapeutic effect. |
front 9 collect data on medications given for behavioral reasons. | back 9 The BCBA NOT can only |
front 10 Not all prescribers take Medicaid take clients with disabilities take clients with a history of behavior problems | back 10 Limitations when selecting a psychiatrist or prescriber |
front 11 Where did they go to school? What kind of volume of patients do they have? Where did they get their training? Have they published any papers? | back 11 Questions we can ask prescribers to learn more about their experience |
front 12 ONE variable/s at a time. | back 12 For a component or parametric analysis to be effective, it is recommended that you change |
front 13 cerebral palsy | back 13 Facilitated Communication Procedure designed for people with |
front 14 a keyboard, typewriter, or letter arrangements that a person can use to type out their responses. | back 14 Facilitated Communication Procedure designed for people with cerebral palsy that involves |
front 15 People who needed assistance | back 15 Who were assigned facilitators who helped them type out their messages. |
front 16 Where did they go to school? What kind of volume of patients do they have? Where did they get their training? Have they published any papers? | back 16 Questions we can ask prescribers to learn more about their experience |
front 17 Capacity to give consent | back 17 Ensures the client understands the risks associated with the medication and can communicate a decision. |
front 18 During the blindfold condition, there were no legible messages typed when the facilitators were blindfolded. In the unshared knowledge condition, the typed messages were always what the therapist saw on their card. | back 18 Outcomes of the single-subject research on facilitated communication |
front 19 Association for Behavior Analysis ABA American Academy of Pediatrics American Speech Language Hearing Association Association for Science in Autism Treatment American Academy of Child and Adolescent Psychiatry | back 19 Organizations against facilitated communication as an effective form of communication. |
front 20 Pairing Shaping Reinforcement | back 20 Use to build a professional relationship with a prescriber |
front 21 were assigned facilitators who helped them type out their messages. | back 21 People who needed assistance |
front 22 Not all prescribers take Medicaid Not all prescribers take clients with disabilities Not all prescribers take clients with a history of behavior problems | back 22 Limitations when selecting a psychiatrist or prescriber |
front 23 Where did they go to school? What kind of volume of patients do they have? Where did they get their training? Have they published any papers? | back 23 Questions we can ask prescribers to learn more about their experience |
front 24 Prescriber is not familiar with single subject designs Prescriber has regulations they have to follow that doesn't include random sequences or drug holidays Prescriber is not interested in conducting an experimental test evaluation | back 24 Reasons a prescriber may not want to design an experimental test evaluation |
front 25 Shaping | back 25 Not asking many questions during the first few sessions and introducing graphs and data slowly over time during the psychotropic drug review is an example of using this strategy to develop a relationship with a prescriber. |
front 26 Attend appropriate medication trainings/workshops Stay up to date with reputable literature on new developments with current medications Stay up to date with the development of new medications that come on the market | back 26 In addition, from your prescriber - additional strategies for staying current on medications |
front 27 Get to know them by interacting with them Very slowly introduce graphs and be sensitive to their reaction to the graphs Ask questions about topics that they are an expert in i.e. side effects, half-life etc. | back 27 Recommended strategies for interacting with your prescriber during the first few sessions |
front 28 Informed consent | back 28 Informs the client about the drug effects and the risk/benefit ratio. |
front 29 Pairing | back 29 Exchanging pleasantries and being positive and nice during the psychotropic drug review is an example of using this strategy to develop a relationship with a prescriber. |
front 30 Shaping | back 30 Not asking many questions during the first few sessions and introducing graphs and data slowly over time during the psychotropic drug review is an example of using this strategy to develop a relationship with a prescriber. |
front 31 Obtain informed consent Cooperate with the prescriber Identify salient behavior targets Identify sensitive measures of the independent variable Create a medication protocol Identify test conditions Design experimental test evaluation (and consider utilizing drug holidays) | back 31 Dr. Blakely's ideal medication evaluation process |
front 32 Multiple Baseline Design | back 32 Only multiple baseline across settings and individuals are options and multiple baseline across settings would require a drug with a short half life. |
front 33 Informed consent | back 33 Informs the client about the drug effects and the risk/benefit ratio. |
front 34 Informed consent | back 34 The participant is informed about the drug effects, side effects and that they have the right to withdraw from the drug evaluation at any time. |
front 35 Capacity to give consent | back 35 Ensures the client understands the risks associated with the medication and can communicate a decision. |
front 36 Voluntarily gives consent | back 36 Ensures consent is not engineered through aversive control or the promise of strong reinforcers. |
front 37 collect data on medications given for behavioral reasons. | back 37 The BCBA NOT can only can |
front 38 Collect data Maintain graphs of data Interface with the prescriber | back 38 *Roles of the BCBA when coordinating with medical personnel |
front 39 medication alone is less effective than medication in concert with behavior analysis services. | back 39 It is TRUE that Many studies demonstrate that |
front 40 Informed consent | back 40 The participant is informed about the drug effects, side effects and that they have the right to withdraw from the drug evaluation at any time. |
front 41 If the drug has severe withdrawal effects If the drug is prescribed for dangerous or severe behavior If the client isn't monitored regularly by staff/caregive | back 41 A drug holiday is not recommended |
front 42 Baseline Placebo Drug | back 42 Conditions that can be included in an experimental design for a drug evaluation |
front 43 Pairing | back 43 Exchanging pleasantries and being positive and nice during the psychotropic drug review is an example of using this strategy to develop a relationship with a prescriber. |
front 44 Capacity to give consent | back 44 Ensures the client understands the risks associated with the medication and can communicate a decision. |
front 45 Physician's Desk Reference (PDR) Drug manufacturer website Prescriber | back 45 Resources for getting information about the side effects of a specific drug apply. |
front 46 Voluntarily gives consent | back 46 Ensures consent is not engineered through aversive control or the promise of strong reinforcers. |
front 47 Pairing | back 47 Exchanging pleasantries and being positive and nice during the psychotropic drug review is an example of using this strategy to develop a relationship with a prescriber. |
front 48 Attend appropriate medication trainings/workshops Stay up to date with reputable literature on new developments with current medications Stay up to date with the development of new medications that come on the market | back 48 In addition, from your prescriber - additional strategies for staying current on medications |
front 49 were assigned facilitators who helped them type out their messages. | back 49 People who needed assistance |
front 50 Single-subject designs | back 50 CAN Be used to evaluate treatments. |
front 51 Parameter of IV | back 51 Parameter of IV – Parametric Analysis |
front 52 It is recommended that you change one variable/s at a time in | back 52 BOTH Behavior and medication |
front 53 Single-subject designs can be used to evaluate treatments and Evaluation of multiple treatments is most effective with Single | back 53 Single-subject designs. |
front 54 The efficacy of a drug is more in Alternating Treatment Design NOT in ALL | back 54 Alternating Treatment Design NOT in ALL |
front 55 Alternating Treatment design can only be used with | back 55 fast acting drugs with a short half-life. |
front 56 The biggest negative effect of the drug holiday is | back 56 the Loss of positive therapeutic effect |
front 57 The BCBA can only collect data on medications given for behavioral reasons? | back 57 Behavioral and non-Behavioral reasons |
front 58 Component analysis helps identify whether a treatment component is | back 58 effective |
front 59 Scientific research its true side effect its true side effect. Then can enhance a drug clinic Vale Limit a... O algo así Scientific research helps determine true side effects, which can improve safe and effective clinical use. | back 59 Enhance the drug’s clinical use (maximize benefits, minimize risks). Limit harmful effects by adjusting dosage, monitoring patients, or providing warnings. |
front 60 Gradual, stepwise dosage adjustments reduce_______ while maximizing_______ | back 60 side effects and toxicity while maximizing therapeutic benefit. |
front 61 Compares the effectiveness of various combinations of a set of interventions | back 61 Component analysis |